Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

@inproceedings{Sommermeyer2016ChimericAR,
  title={Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo},
  author={Daniel Sommermeyer and Michael Hudecek and Paula L. Kosasih and Tea Gogishvili and David G Maloney and Cameron J Turtle and Stanley R Riddell},
  booktitle={Leukemia},
  year={2016}
}
Adoptive T-cell therapy with gene-modified T cells expressing a tumor-reactive T-cell receptor or chimeric antigen receptor (CAR) is a rapidly growing field of translational medicine and has shown success in the treatment of B-cell malignancies and solid tumors. In all reported trials, patients have received T-cell products comprising random compositions of CD4+ and CD8+ naive and memory T cells, meaning that each patient received a different therapeutic agent. This variation may have… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 26 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 78 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Similar Papers

Loading similar papers…